Last reviewed · How we verify
NCT03090724
Pharmacokinetics of BIA 5-453 and Its Metabolites
Phase 1 trial testing BIA 5-453 in Hypertension in 25 participants. Completed in 12 August 2008.
12 August 2008
Quick facts
| Lead sponsor | Bial - Portela C S.A. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 13 June 2008 |
| Primary completion | 12 August 2008 |
| Estimated completion | 12 August 2008 |
| Sites | 1 location across France |
Drugs / interventions tested
- BIA 5-453 — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
- Chronic Heart Failure — all drugs for Chronic Heart Failure →
Sponsor
Bial - Portela C S.A. — full company profile →
Who can join
18 and older, male only, with Hypertension or Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to assess the effects of age on the pharmacokinetic (PK) profile of BIA 5-453 and its metabolites.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03090724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BIA 5-453
Trials testing the same drug.
- NCT03090568 — Bioavailability Study of BIA 5-453 · Phase 1 · completed
- NCT03099226 — Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453 · Phase 1 · completed
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Bial - Portela C S.A. trials
Trials by the same sponsor.
- NCT07403799 — REal-life ON PARKinson's - ITaly (REONPARK-IT) · recruiting
- NCT04990284 — eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. · Phase 4 · completed
- NCT04986995 — OpicApone Sleep dISorder · Phase 4 · completed
- NCT04978597 — Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) · Phase 3 · completed
- NCT04986982 — OpiCapone Effect on Motor Fluctuations and pAiN · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03090724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bial - Portela C S.A.
- Last refreshed: 27 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03090724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing